Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: Results from a pilot study

Journal of Diabetes Science and Technology

Volumn 3, Issue 6, 2009, Pages 1442-1450

  Musholt, Petra B ^a,b   Schöndorf, Thomas ^a,c,d   Pfützner, Andreas ^a,d   Hohberg, Cloth ^a   Kleine, Iris ^e   Fuchs, Winfried ^e   Hehenwarter, Silvia ^a   Dikta, Gerhard ^f   Kerschgens, Benedikt ^a   Forst, Thomas ^a,b  

^a Institute for Clinical Research and Development   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF APPLIED SCIENCES   (Germany)

^e Takeda Pharma GmbH   (Germany)

^f AACHEN UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Cardiovascular risk; Glycemic control; Pioglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ADIPONECTIN, HUMAN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; METFORMIN; PIOGLITAZONE; PROINSULIN;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PILOT STUDY; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADIPONECTIN; ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; METFORMIN; MIDDLE AGED; PILOT PROJECTS; PROINSULIN; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957322891     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300626     Document Type: Article

References (38)

1. Samanta A, Burden AC, Jones GR, Clarkson L. The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy. Diabetes Res. 1986;3(5):269-71. (Pubitemid 16057253)
2. Biesenbach G, Grafinger P, Raml A. Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy. Wien Klin Wochenschr. 2006;118(17-18):543-8. (Pubitemid 44579747)
3. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753-60. (Pubitemid 351697950)
4. Pfützner A, Schneider CA, Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther. 2006;4(4):445-59.
5. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. (Pubitemid 15018832)
6. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. Diabet Med. 2000;17(4):299-307. (Pubitemid 30266125)
7. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292(3):E871-83. (Pubitemid 46411067)
8. Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Numao T, Fukuda T, Shimada K, Kario K. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res. 2007;30(1):23-30.
9. Forst T, Karagiannis E, Lübben G, Hohberg C, Schöndorf T, Dikta G, Drexler M, Morcos M, Dänschel W, Borchert M, Pfützner A. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis. 2008;197(1):311-7. (Pubitemid 351273253)
10. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12(5):413-23. (Pubitemid 32664824)
11. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26(9):2493-9. (Pubitemid 37055444)
12. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89(12):6068-76. (Pubitemid 39628416)
13. Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M, GLAC Study Group. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes. Diabet Med. 2004;21(8):859-66. (Pubitemid 39036999)
14. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, Quartet Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22(4):399-405. (Pubitemid 40516237)
15. Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner AH, Kann P, Forst T. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res. 2005;37(8):510-5.
16. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111(1):10-7. (Pubitemid 32635256)
17. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, Quartet Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141-7. (Pubitemid 38196723)
18. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000;22(12):1395-409. (Pubitemid 32056079)
19. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167-74. (Pubitemid 40467663)
20. Bonora E. Protection of pancreatic beta-cells: is it feasible? Nutr Metab Cardiovasc Dis. 2008;18(1):74-83. (Pubitemid 50020512)
21. Pfützner A, Pfützner AH, Larbig M, Forst T. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther. 2004;6(3):405-12.
22. Pfützner A, Standl E, Hohberg C, Konrad T, Strotmann HJ, Lübben G, Langenfeld MR, Schulze J, Forst T. IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. Diabetes Technol Ther. 2005;7(3):478-86.
23. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk - the PIOSTAT Study. Metabolism. 2007;56(4):491-6. (Pubitemid 46437254)
24. Schöndorf T, Maiworm A, Emmison N, Forst T, Pfützner A. Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab. 2005;51(9-10):489-94.
25. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006;8(3):264-80.
26. Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2006;65(6):722-8. (Pubitemid 44772351)
27. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53(8):2169-76. (Pubitemid 38970772)
28. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89(9):4312-9. (Pubitemid 39244431)
29. Otto C, Otto B, Göke B, Pfeiffer AF, Lehrke M, Vogeser M, Spranger J, Parhofer KG. Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest. 2006;29(3):231-6.
30. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005;6(1):13-21.
31. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109(16):1955-9. (Pubitemid 38544485)
32. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391-7.
33. Pfützner A, Standl E, Strotmann HJ, Schulze J, Hohberg C, Lübben G, Pahler S, Schöndorf T, Forst T. Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus. Clin Chem Lab Med. 2006;44(5):556-60.
34. Heliövaara MK, Herz M, Teppo AM, Leinonen E, Ebeling P. Pioglitazone has anti-inflammatory effects in patients with type 2 diabetes. J Endocrinol Invest. 2007;30(4):292-7.
35. Takase H, Nakazawa A, Yamashita S, Toriyama T, Sato K, Ueda R, Dohi Y. Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism. 2007;56(4):559-64. (Pubitemid 46437253)
36. Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007;30(5):387-94. (Pubitemid 46958888)
37. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007;49(3):290-7. (Pubitemid 46110954)
38. Maegawa H, Nishio Y, Nakao K, Ugi S, Maeda K, Uzu T, Kashiwagi A. Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. Endocr J. 2007;54(4):613-8. (Pubitemid 47414611)